key: cord-0891163-2o4fnekk
authors: Dragoni, Filippo; Schiaroli, Elisabetta; Micheli, Valeria; Fiaschi, Lia; Lai, Alessia; Zehender, Gianguglielmo; Rossetti, Barbara; Gismondo, Maria Rita; Francisci, Daniela; Zazzi, Maurizio; Vicenti, Ilaria
title: Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies
date: 2022-03-15
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.03.005
sha: 76906c8f50e445254b7cd149b70603545de7c680
doc_id: 891163
cord_uid: 2o4fnekk

nan

Among the different SARS-CoV-2 variants of concern (VOCs) [1], delta and omicron currently account 29

for the vast majority of cases worldwide, with the latter rapidly replacing the former in many 30

countries [2] . Notably, omicron is the most divergent from the wild type B.1 strain, with 15 amino 31 acid changes in the receptor-binding domain of the spike protein, the major target of neutralizing 32

antibodies. Indeed, omicron partly escapes natural or vaccine-elicited immunity [3] and can decrease 33 the efficacy of currently licensed therapeutic monoclonal antibodies (mAbs) [4, 5]. 34 35 We assessed the ex vivo inhibition of omicron and delta variants by sera obtained from unvaccinated 36 patients treated with one of the three licensed mAb preparations, namely 37 bamlanivimab/etesevimab, casirivimab/imdevimab and sotrovimab. A pair of patient sera was 38 collected, the first before (to exclude any prior NtAb activity) and the second one hour post mAbs 39

infusion. Figure 1) . 78

SARS-CoV-2 AY.4.2 131 variant circulating in Italy: Genomic preliminary insight

Single-dose BNT162b2 mRNA 134 COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers 135 recovering from asymptomatic or mild natural SARS-CoV-2 infection

Reduced 138 sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate

A previous report documented in vitro inhibition of the delta variant by the individual mAbs 80 etesevimab, casirivimab and imdevimab, but not bamlanivimab, at slightly higher levels compared 81 with the wild type B.